Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 Next >
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Appoints Chris Degnan as Chief Financial Officer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback